Urinary matrix metalloproteinase‐7 level is associated with the presence of metastasis in bladder cancer
- 3 September 2010
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 107 (7) , 1069-1073
Abstract
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Recent data suggest that MMP‐7 is critically involved in metastasis formation. In accordance, we formerly found significantly elevated MMP‐7 tissue expression and serum concentration in samples of patients with metastatic bladder cancer and observed an independent correlation between MMP‐7 levels and patients’ prognosis. In the present study we demonstrated that high preoperative urinary MMP‐7 concentrations are associated with metastatic bladder cancer. OBJECTIVE: • To assess the presence of matrix metalloproteinase (MMP)‐7 in urine samples of patients with bladder cancer and to investigate the correlation between MMP‐7 urine concentration and clinicopathological variables. PATIENTS AND METHODS: • The presence of MMP‐7 in the urine of patients with bladder cancer was tested in 32 representative cases using immunoprecipitation followed by western blot analysis. • Urinary MMP‐7 concentration levels were analyzed in 132 patients with bladder cancer and 96 controls using an enzyme‐linked immunosorbent assay. RESULTS: • MMP‐7 levels did not differ significantly between patients with localized bladder cancer and controls ( P = 0.174). On the other hand, we detected a fourfold, significantly elevated MMP‐7 concentration in urine samples of patients with bladder cancer with regional or distant metastasis ( P = 0.003). • Using a threshold value of 6.88 ng/ml, determined by receiver‐operating characteristic curve analysis, a specificity of 82% and a sensitivity of 78% were observed. • Western blot analysis revealed that the 55‐kDa tissue inhibitor of metalloproteinase 1 complexed MMP‐7 is the dominant form of urinary matrilysin. CONCLUSIONS: • MMP‐7 is present in detectable amounts in the urine of patients with bladder cancer. Its concentrations are significantly elevated in patients with metastatic disease. • Determination of urinary matrilysin level could help to detect bladder cancer metastasis, and may therefore provide a more reliable prognosis and influence therapy decisions.Keywords
This publication has 15 references indexed in Scilit:
- Plasma matrix metalloproteinase‐7 as a metastatic marker and survival predictor in patients with renal cell carcinomasCancer Science, 2008
- Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patientsInternational Journal of Cancer, 2007
- Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and MetastasisClinical Cancer Research, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic CancerClinical Cancer Research, 2004
- MT1-MMP and MMP-7 in invasion and metastasis of human cancersCancer and Metastasis Reviews, 2003
- Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancerThe Journal of Pathology, 2003
- Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Pancreatic Adenocarcinomas: Clinicopathologic and Prognostic Significance of Matrilysin ExpressionJournal of Clinical Oncology, 2001
- Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancersInternational Journal of Cancer, 2000
- Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinomaGastroenterology, 1997